Assessment of the real-life usage of intravitreal dexamethasone implant in the treatment of chronic diabetic macular edema in France

Journal of Ocular Pharmacology and Therapeutics

Volumn 32, Issue 6, 2016, Pages 383-389

  Querques, Giuseppe ^a,b   Darvizeh, Fatemeh ^b   Querques, Lea ^b   Capuano, Vittorio ^a   Bandello, Francesco ^b   Souied, Eric H ^a  

^a CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; DRUG IMPLANT;

ARTICLE; CLINICAL ARTICLE; CLINICAL PRACTICE; DIABETIC MACULAR EDEMA; FOLLOW UP; HUMAN; INJECTION; INTRAVITREAL IMPLANT; OPHTHALMOLOGIST; OUTCOME ASSESSMENT; PHARMACY; PRESCRIPTION; QUESTIONNAIRE; REIMBURSEMENT; SOCIAL SECURITY; TREATMENT DURATION; ADMINISTRATION AND DOSAGE; AGED; DIABETIC RETINOPATHY; DRUG IMPLANT; FRANCE; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; THERAPEUTIC USE;

AGED; DEXAMETHASONE; DIABETIC RETINOPATHY; DRUG IMPLANTS; FRANCE; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA;

EID: 84979000420     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2016.0010     Document Type: Article

References (25)

1. Porta, M., and Bandello, F. Diabetic retinopathy. A clinical update. Diabetologia. 45: 1617-1634, 2002.
2. Frank, R.N. Diabetic retinopathy. N. Engl. J. Med. 350: 48-58, 2004.
3. Delcourt, C., Massin, P., and Rosilio, M. Epidemiology of diabetic retinopathy: Expected vs reported prevalence of cases in the French Population. Diabetes Metab. 35: 431-438, 2009.
4. DCCT-The diabetes control and complications trial research group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329: 977-986, 1993.
5. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 38. BMJ. 317: 703-713, 1998.
6. Nguyen, Q.D., Brown, D.M., Marcus, D.M., et al. Ranibizumab for diabetic macular edema: Results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 119: 789-801, 2012.
7. Elman, M.J., Ayala, A., Bressler, N.M., et al. Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology. 122: 375-381, 2015.
8. Korobelnik, J.F., Do, D.V., Schmidt-Erfurth, U., et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 121: 2247-2254, 2014.
9. Naresh, K.Y., Chaitra, J., Anand, R., and Manish, N. Recent developments in retinal lasers and delivery systems. Indian J. Ophthalmol. 62: 50-54, 2014.
10. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. ETDRS Report Number 1. Arch. Ophtalmol. 103: 1796- 1806, 1985.
11. Ford, J.A., Lois, N., Royle, P., Clar, C., Shyangdan, D., and Waugh, N. Current treatments in diabetic macular oedema: Systematic review and meta-analysis. BMJ. 3: E002269, 2013.
12. European Medical Agency. Lucentis summary of product characteristics. EMA. 000715/WC500043546.
13. Wells, J.A., Glassman, A.R., Ayala, A.R., et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: Two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 123: 1351-1359, 2016.
14. Bressler, S.B., Ayala, A.R., Bressler, N.M., et al. Persistent macular thickening after ranibizumab treatment for diabetic macular edema with vision impairment. JAMA Ophthalmol. 134: 278-285, 2016.
15. Gillies, M.C., Kuzniarz, M., Craig, J., Ball, M., and Luo, W. Simpson, JM. Intravitreal triamcinolone induced elevated intraocular pressure is associated with the development of posterior subcapsular cataract. Ophthalmology. 112: 139-143, 2005.
16. Agence Nationale de Sécurité du Médicament. Cas de pharmacovigilance avec troubles visuels incluant des cas de cécité à la suite d'administration intraoculaire de KENACORT RETARD au cours d'utilisations hors AMM. Information Destinée aux Ophtalmologistes. 2007.
17. Elman, M.J., Aiello, L.P., Beck, R.W., et al. Diabetic retinopathy clinical research network. Ophthalmology. 117: 1064-1077, 2010.
18. Haller, J.A., Bandello, F., Belfort, R., et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 117: 1134-1146, 2010.
19. Boyer, D.S., Yoon, Y.H., Belfort, R.J., et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 121: 1904-1914, 2014.
20. European Medical Agency. Ozurdex European public assessment report. EMA. 492068, 2014.
21. Haute Autorité de la Santé. Commission de Transparence- Avis. OZURDEX 700 microgrammes, implant intravitréen avec applicateur 2015.
22. Callanan, D.G., Gupta, S., Boyer, D.S., et al. Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. Ophthalmology. 120: 1843-1851, 2013.
23. Guigou, S., Hajjar, C., Parrat, E., et al. Multicenter Ozurdex - assessment for diabetic macular edema: MOZART study. JFO. 37, 480-485, 2014.
24. Gillies, M.C., Lyndell, L.L., Campain, A., et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: The BEVORDEX study. Ophthalmology. 121: 2473-2481, 2014.
25. Scaramuzzi,M., Querques, G., La Spina, C.L., and Lattanzio, R. Bandello, F. Repeated intravitreal dexamethasone implant (Dexamethasone implant) for diabetic macular edema. Retina. 35: 1216-1222, 2015.